ChristianaCare is a regional leader in obstetrics and maternal fetal medicine research and is a member of the National Institute of Child Health and Human Development’s Maternal Fetal Medicine Unit Network. The network focuses on clinical questions in maternal fetal medicine and obstetrics, particularly with respect to the continuing problem of preterm birth.
Ob/Gyn research at ChristianaCare focuses on the following health concerns for newborns and new mothers:
Research efforts are supported by the staff and resources of ChristianaCare, one of the nation’s top providers of obstetric services and one of the largest and most experienced maternity centers and neonatal intensive care units in the Delaware Valley. Email OB/GYN Research.
ChristianaCare’s Cancer Research Program is part of a select group of 46 research centers (34 community sites and 12 minority/under-served sites) in the United States and Puerto Rico that are funded by the National Cancer Institute to participate in the NCI Community Oncology Research Program (NCORP).
At any given time, we have at least 700 patients enrolled in as many as 100 different clinical trials.
Thousands of patients throughout the Delaware region have benefited from studies conducted under the auspices of the NCORP, as well as from a variety of other federally funded and industry-supported cancer treatment, prevention and control trials. Many of these trials take place on a national or international level at approved research centers around the country and throughout the world.
ChristianaCare also takes part in NCI-funded Cancer Care Delivery Research (CCOR) which is focused on patient, provider and organizational -level influences on cancer outcomes.
Clinical trials test new drugs and combinations of treatments, as well as new techniques using surgery, radiation therapy, gene therapy, immunotherapy and biologics. Research studies encompass a wide range of cancer-related disciplines including hematology/oncology, radiation oncology and gynecologic oncology.
Clinical trials offered by ChristianaCare attract participants from Delaware, New Jersey, Maryland and Pennsylvania. Delaware research affiliates that include Beebe Healthcare, Tunnell Cancer Center and Nanticoke Health Services Cancer Care Center participate in NCI research. Our annual accrual rate - which measures the percentage of patients enrolled in clinical trials - among newly diagnosed cancer patients is among the highest in the nation.
All studies are first approved by the National Cancer Institute Central Institutional Review Board and/or ChristianaCare’s Institutional Review Board, a special committee that reviews and oversees all research projects to ensure that participants’ rights and welfare are protected.
ChristianaCare’s Diabetes & Metabolic Diseases Research Program is part of the ChristianaCare Research Institute and has participated in more than 100 clinical trials involving inpatients and outpatients. The research has covered various aspects and phases of diabetes-related illnesses and treatments, including: